Jefferson Institute for Bioprocessing: Site plan and launch update

By Flora Southey contact

- Last updated on GMT

A rendering of the Jefferson Institute for Bioprocessing at Spring House Innovation Park, Pennsylvania, US
A rendering of the Jefferson Institute for Bioprocessing at Spring House Innovation Park, Pennsylvania, US
The Jefferson Institute for Bioprocessing is set to launch in spring 2019, in Jefferson University’s new Spring House Innovation Park.

Philadelphia’s Jefferson University – the result of a merger between Philadelphia University and Thomas Jefferson University – has announced its bioprocessing institute will open in the first half of 2019.

The 133-acre Spring House Innovation Park campus, located in Lower Gwynedd, Pennsylvania, will house the 25,000 sq. ft. Institute, designed to educate 2,500 people per year, including industry professionals and Jefferson University students.

“Our facility at Spring House Innovation Park will utilise leading-edge biopharmaceutical manufacturing technology and support current and future workforce demands in this critically important field,” ​said associate provost for applied research at Jefferson (Philadelphia University + Thomas Jefferson University) Ron Kander in a statement.

The Jefferson Institute for Bioprocessing was first announced in partnership with Ireland’s National Institute for Bioprocessing Research and Training (NIBRT) in February this year​.

At the time, NIBRT CEO Dominic Carolan said the new Institute responds to an increased demand for biologic drugs: “There is a significant demand for global talent to support the growth of the biopharmaceutical manufacturing industry and our relationship with Jefferson will help address this demand throughout the United States.”

Related news

Show more

Related products

show more

Strategies for Upstream Intensification

Strategies for Upstream Intensification

Take the Right Path Upstream with MilliporeSigma | 01-Sep-2020 | Technical / White Paper

The Facility of the Future represents a transformation in how biologics are developed and manufactured.

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 05-Aug-2020 | Technical / White Paper

Traditional methods for adventitious agent testing rely on biological amplification and detection, which can take several weeks. This time-consuming approach...

Related suppliers

Follow us

Products

View more

Webinars